The analysis of prolonged-release drugs at the Ukrainian pharmaceutical market
DOI:
https://doi.org/10.24959/sphhcj.21.228Keywords:
prolonged-release drugs; marketing analysis; tablets; nonsteroidal anti-inflammatory drugsAbstract
Aim. To analyze the range of prolonged-release dosage forms at the Ukrainian pharmaceutical market focusing on the pharmacotherapeutic groups that are insufficiently saturated with prolonged-release drugs, in particular to determine the proportion of non-steroidal anti-inflammatory drugs (NSAIDs).
Materials and methods. The research was conducted in accordance with the data of the State Registry of Medicines of Ukraine and the АТС classification system. The methods of scientific analysis, in particular methods of grouping and comparison, marketing methods of analysis were applied.
Results. The study of the assortment of prolonged-release drugs registered at the Ukrainian pharmaceutical market has been performed. The structure of the assortment by manufacturer, dosage forms, the АТС classification system has been analyzed. As a result of the study, it has been found that 202 trade names of prolonged-release drugs are registered in Ukraine. Most of them (196 names, 84 %) are medicines of foreign manufacturers. Prolonged-release drugs registered in Ukraine are mostly presented in the form of tablets and capsules, but tablets (72.77 %) are the largest part. The analysis of distribution of prolonged-release drugs by the ATC classification groups has shown that a significant number of prolonged-release drugs belongs to group N – Nervous system (80 trade names), and group C – Cardiovascular system (44 trade names). The share of group M – Musculoskeletal system, in particular prolonged-release NSAIDs, is insignificant (9 trade names).
Conclusions. The marketing research of the prolonged-release drugs conducted allowed us to characterize the structure of the assortment of the Ukrainian market by pharmacotherapeutic groups, manufacturers and dosage forms. As a result of the research, the current assortment of prolonged-release NSAIDs has been determined.
References
Промислова технологія лікарських засобів: навчальний посібник для самостійної роботи студентів / О.А. Рубан, В.Д. Рибачук, Л. М. Хохлова та ін. Харків: НФаУ. 2015. 120 с.
Goyal S., Agarwal G., Agarwal S. et al. Oral sustained release tablets: An overview with a special emphasis on matrix tablet. American Journal of Advanced Drug Delivery. 2017. Vol. 5, Iss. 2. P. 064-076. DOI: https://doi.org/10.21767/2321-547X.1000013.
Kumar A., Aeila A. Sustained release matrix type drug delivery system: An overview. World Journal of Pharmacy and Pharmaceutical Sciences. 2019. Vol. 9, Iss. 1. P. 470-480. DOI: https://doi.org/10.20959/wjpps20201-15241.
Modified release dosage forms: giving new life to drugs. Contract Pharma. 2020. URL: https://www.contractpharma.com/csd/profile/recro-gainesville/view_modified-release-dosage-forms-giving-new-life-to-drugs/.
Revel J., Gorria P. Modified-release formulations: improving efficacy and patient compliance. Pharmaceutical Technology. 2019. Iss. 2. P. s6–s8.
Strategies to modify the drug release from pharmaceutical systems / M. Bruschi. Amsterdam: Elsevier/Woodhead Publishing. 2017. 208 p. URL: https://www.elsevier.com/books/strategies-to-modify-the-drug-release-from-pharmaceutical-systems/bruschi/978-0-08-100092-2.
Deo S. Modified release drug delivery systems. Concept Pharma. 2017. DOI: https://doi.org/10.13140/RG.2.2.30034.15046
Кучеренко Н.В., Гудзенко Н.В. Аналіз фармацевтичного ринку України в аспекті твердих оральних лікарських засобів з відтермінованою дією. ScienceRise. Pharmaceutical Science. 2017. № 3. С. 4-8. DOI: https://doi.org/10.15587/2519-4852.2017.103327.
Gujral G., Kapoor D., Jaimini M. An updated review on modified release tablets. Journal of Drug Delivery and Therapeutics. 2018. Vol. 8, Iss. 4. P. 5-9. DOI: https://doi.org/10.22270/jddt.v8i4.1722.
Lewis A. Modified release – alternative strategies for development of modified-release dosage forms. Drug development. 2019. URL: https://drug-dev.com/modified-release-alternative-strategies-for-development-of-modified-release-dosage-forms/.
Демчук М. Б., Грошовий Т. А., Найда Ю. В. та ін. Сучасний стан створення, виробництва та дослідження таблетованих лікарських препаратів. Повідомлення 29. Характеристика процесу розробки та дослідження матричних таблеток. Фармацевтичний часопис. 2019. № 2. C. 103-111. DOI https://doi.org/10.11603/2312-0967.2019.2.10197.
Державний реєстр лікарських засобів України. URL: http://www.drlz.com.ua/.
Головач І.Ю. Вибір НПЗП при остеоартриті: доказова чи персоналізована медицина? Ревматичні хвороби: межі повноважень популяційних та персоніфікованих методів лікування: матеріали наук.-практ. конф., м. Київ, 16-17 бер. 2017. URL: https://health-ua.com/article/25908-vibr-npzp-pri-osteoartrit--dokazova-chi-personalzovana-meditcina.
Зазірний І.М. Ефективність застосування препарату Німедар в ортопедичній практиці. Травма. 2018. Т. 19, № 2. С. 19-27. URL: http://nbuv.gov.ua/UJRN/Travma_2018_19_6_5.
Имаметдинова Г.Р, Чичасова Н.В. Лечение остеоартрита: фокус на нимесулид. Современная ревматология. 2017. Т. 11, № 2. С. 80–87. DOI: https://doi.org/10.14412/1996-7012-2017-2-80-87.
Шуба Н. М., Воронова Т. Д., Пилипенко А. В. та ін. Эффективность нимесулида и его влияние на отдельные катаболические и анаболические факторы у больных остеоартрозом. Укр. ревматол. журн. № 1 (63). С. 57-60.
Компендіум – лекарственные препараты. URL: https://compendium.com.ua/.
Котвіцька А. А., Костюк В. Г. Маркетингові дослідження фармацевтичного ринку нестероїдних протизапальних лікарських засобів. Фармацевтичний часопис. 2016. № 2. С. 48–53. URL: http://nbuv.gov.ua/UJRN/Phch_2016_2_12.
Controlled Release Roundtable. American Pharmaceutical Review. 2017. Vol. 20, Iss 4. URL: https://www.americanpharmaceuticalreview.com/Featured-Articles/339678-Controlled-Release-Roundtable/.
Ruban, O. A., Rybachuk, V.D., Khokhlova, L.M., Maslii, Y. S., Spyrydonov, S.V., Herbyna, N.A. (Eds.). (2015). Promyslova tekhnolohiia likarskykh zasobiv. Kharkiv: NFaU.
Goyal, S., Agarwal, G., Agarwal, S., Karar, P. (2017). Oral sustained release tablets: an overview with a special emphasis on matrix tablet. American Journal Of Advanced Drug Delivery, 5(2), 064-076. doi: https://doi.org/10.21767/2321-547X.1000013.
Kumar, A., Aeila, A. (2019). Sustained release matrix type drug delivery system: an overview. World Journal Of Pharmacy And Pharmaceutical Sciences, 9 (1), 470–480. doi: https://doi.org/10.20959/wjpps20201-15241.
Modified release dosage forms: giving new life to drugs. Contract Pharma Magazine. 2020. Available at: https://www.contractpharma.com/csd/profile/recro-gainesville/view_modified-release-dosage-forms-giving-new-life-to-drugs/
Revel, J., Gorria, P. (2019). Modified-release formulations: improving efficacy and patient compliance. Pharmaceutical Technology, (2), s6–s8.
Bruschi, M. (2017). Strategies to modify the drug release from pharmaceutical systems. Amsterdam: Elsevier/Woodhead Publishing, 208. Available at: https://www.elsevier.com/books/strategies-to-modify-the-drug-release-from-pharmaceutical-systems/bruschi/978-0-08-100092-2.
Deo, Shreyas. (2017). Modified release drug delivery systems. Concept Pharma. doi: https://doi.org/10.13140/RG.2.2.30034.15046.
Kucherenko, N. V., Hudzenko, O. P. (2017). Analiz farmatsevtychnoho rynku ukrainy v aspekti tverdykh oralnykh likarskykh zasobiv z vidterminovanoiu diieiu. ScienceRise. Pharmaceutical Science, (3), 4-8. doi: https://doi.org/10.15587/2519-4852.2017.103327.
Gujral, G., Kapoor, D., Jaimini, M. (2018). An updated review on modified release tablets. Journal of Drug Delivery and Therapeutics, 8(4), 5-9. doi: https://doi.org/10.22270/jddt.v8i4.1722.
Lewis, A. (2019). Modified release – alternative strategies for development of modified-release dosage forms. Drug development. Available at: https://drug-dev.com/modified-release-alternative-strategies-for-development-of-modified-release-dosage-forms/.
Demchuk, M. B., Hroshovyi, T. A., Nayda, Y. V., Koval, V. M. (2019). Suchasnyi stan stvorennia, vyrobnytstva ta doslidzhennia tabletovanykh likarskykh preparativ. Povidomlennia 29. Kharakterystyka protsesu rozrobky ta doslidzhennia matrychnykh tabletok. Farmatsevtychnyi chasopys, (2), 103–111. doi: https://doi.org/10.11603/2312-0967.2019.2.10197.
Derzhavnyi reiestr likarskykh zasobiv Ukrainy. Available at: http://www.drlz.com.ua/.
Holovach, I.Yu. (2017). Vybir NPZP pry osteoartryti: dokazova chy personalizovana medytsyna? Revmatychni khvoroby: mezhi povnovazhen populiatsiinykh ta personifikovanykh metodiv likuvannia, materialy naukovo-praktychnoi konferentsii. Available at: https://health-ua.com/article/25908-vibr-npzp-pri-osteoartrit--dokazova-chi-personalzovana-meditcina.
Zazirnyi, I. M. (2018). Efektyvnist zastosuvannia preparatu Nimedar v ortopedychnii praktytsi. Travma. 19 (2), 19-27.
Ymametdynova, H.R., Chychasova, N.V. (2017). Lechenye osteoartryta: fokus na nymesulyd. Sovremennaia revmatolohyia. 11(2), 80-87. doi: https://doi.org/10.14412/1996-7012-2017-2-80-87.
Shuba, N. M., Voronova, T. D., Pylypenko, A. V., Lytvynenko, S. V. (2016). Effektivnost nimesulida i ego vliianie na otdelnye katabolicheskie i anabolicheskie faktory u bolnykh osteoartrozom. Ukrainskyi revmatolohichnyi zhurnal, 1(63), 57-60.
Kompendium – lekarstvennye preparaty. Available at: https://compendium.com.ua/.
Kotvitska, A. A., Kostiuk, V. H. (2016). Marketynhovi doslidzhennia farmatsevtychnoho rynku ne steroidnykh protyzapalnykh likarskykh zasobiv. Farmatsevtychnyi chasopys, (2), 48-53. Available at: http://nbuv.gov.ua/UJRN/Phch_2016_2_12.
Controlled Release Roundtable. (2017). American Pharmaceutical Review. 20 (4). Available at: https://www.americanpharmaceuticalreview.com/Featured-Articles/339678-Controlled-Release-Roundtable/.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
